ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2017

Go back to ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2017

Jefferies Cuts Price Target on ResMed (RMD) to $56 Following 1Q Miss

October 26, 2016 7:11 AM EDT

Jefferies maintained an Underperform rating on ResMed (NYSE: RMD), and cut the price target to $56.00 (from $58.00), following the company's 1Q earnings report. ResMed reported a $10mn revenue miss on a $0.02 EPS miss. Organic growth of 3% drove EPS growth of 7%; however, excluding... More

ResMed (RMD) Misses Q1 EPS by 2c

October 25, 2016 4:12 PM EDT

ResMed (NYSE: RMD) reported Q1 EPS of $0.62, $0.02 worse than the analyst estimate of $0.64. Revenue for the quarter came in at $465.4 million versus the consensus estimate of $474.73 million.

For earnings history and earnings-related data on ResMed (RMD) click here.

... More